CR 2093

cholecystokinin receptor antagonist

Also Known As:

4-(3-chlorobenzamido)-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; CR-2093; CR2093; Pentanoic acid, 4-((3-chlorobenzoyl)amino)-5-((3,3-dimethylbutyl)amino)-5-oxo-, (R)-

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Amino Acids: 30675
  - CR 2093: 2

Related Diseases

Adenocarcinoma

11/01/1995 - "The purpose of this study was to determine the effect of the gastrin receptor antagonist, CR2093, on basal and gastrin-stimulated growth of primary human colorectal adenocarcinomas and to relate this to gastrin receptor expression. "
06/01/1992 - "The gastrin receptor antagonist, CR2093, competed with 125I-gastrin-17 (5 x 10(-10) M) for binding to gastrin receptors on the rat pancreatic adenocarcinoma, AR42J (CR2093 concentration inducing 50% of 125I-gastrin-17 binding (IC50) was 8 x 10(-5) M), on the human gastric adenocarcinoma, MKN45 (IC50 5.5 x 10(-5) M) and the human colo-rectal adenocarcinoma C523 (IC50 greater than 10(-4) M). "

Related Drugs and Biologics

1.	Cholecystokinin B Receptor
2.	Gastrins
3.	gastrin 17 (G 17)